

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
Durability of biochemical improvements through six years of open label treatment with obeticholic acid in patients with primary biliary cholangitis who did not achieve the POISE criteria	Hirschfield	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI146
Predicted risk of end stage liver disease utilizing the UK-PBC risk score with continued standard of care and subsequent addition of obeticholic acid for 60 Months in patients with primary biliary cholangitis	Jones	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract THU114
Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study	Leroy	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI180
<i>NASH</i>		
Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the REGENERATE study	Younossi	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI080
Obeticholic acid (OCA) improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study	Boursier	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract AS075
Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the REGENERATE trial	Loomba	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI066
The burden of disease associated with non-alcoholic steatohepatitis patients under standard of care	Pais	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract THU048
Noninvasive tests for assessing fibrosis in patients with non-alcoholic fatty liver disease: an evaluation of combining test results	Vick	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract FRI009
Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: results of a post hoc analysis from the interim analysis of the REGENERATE study	Loomba	https://ilc-congress.eu/wp-content/uploads/2020/08/digital-ilc-2020-abstract-book-20-august.pdf Abstract LBP19

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
Durability of Biochemical Improvements Through Six Years of Open-Label Treatment With Obeticholic Acid in Patients with PBC who Did Not Achieve the POISE Criteria	Hirschfield	https://doi.org/10.1016/S0016-5085(20)33875-0 Abstract 687
Predicted Risk of End-Stage Liver Disease Utilising the UK-PBC Risk Score With Continued Standard of Care and Subsequent Addition of Obeticholic Acid for 60 Months in Patients With Primary Biliary Cholangitis	Jones	https://doi.org/10.1016/S0016-5085(20)34100-7 Abstract Su1647
<i>NASH</i>		
Obeticholic acid (OCA) improves experimental noninvasive markers of NASH and advanced fibrosis: results of a secondary analysis from the month-18 interim analysis of the REGENERATE study	Boursier	https://doi.org/10.1016/S0016-5085(20)33836-1 Abstract 334
Obeticholic Acid Improves Hepatic Fibroinflammation as Assessed by Multiparametric Magnetic Resonance Imaging: Interim Results of the REGENERATE Trial	Lomba	https://doi.org/10.1016/S0016-5085(20)34278-5 Abstract Tu1665
Obeticholic Acid Improves Transaminases in Patients With Non-alcoholic Steatohepatitis: Results From the 18-Month Interim Analysis of the REGENERATE Study	Rinella	https://doi.org/10.1016/S0016-5085(20)34184-6 Abstract Mo1448
Obesity-specific Health-related Quality of Life In Patients With Non-alcoholic Steatohepatitis: Results From the REGENERATE Study	Younossi	https://doi.org/10.1016/S0016-5085(20)33828-2 Abstract 326

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
Effects of Obeticholic Acid on APRI and GLOBE Score in Patients with Primary Biliary Cholangitis	Harms	https://doi.org/10.1002/hep.30941 Abstract 1261
Durable Response in the Markers of Cholestasis Through 5 Years of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis	Nevens	https://doi.org/10.1002/hep.31033 Late Breaking Abstract 06
<i>NASH</i>		
Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): A secondary analysis of the phase 3 REGENERATE study	Anstee	https://doi.org/10.1002/hep.30941 Abstract 1715
Obeticholic Acid Treatment in Patients with Non-Alcoholic Steatohepatitis: A Secondary Analysis of the REGENERATE Study Across Fibrosis Stages	Sanyal	https://doi.org/10.1002/hep.30940 Abstract 34
The impact of pruritus on patient-reported outcomes in patients with non-alcoholic steatohepatitis treated with obeticholic acid	Younossi	https://doi.org/10.1002/hep.30940 Abstract 56
Assessment of patient-reported outcomes in patients with NASH treated with obeticholic acid: Results from REGENERATE phase 3 clinical trial	Younossi	https://doi.org/10.1002/hep.30941 Abstract 2324
Safety, Pharmacokinetics and Pharmacodynamics of Obeticholic Acid in Patients with Nonalcoholic Steatohepatitis and Fibrosis or Cirrhosis	Alkhoury	https://doi.org/10.1002/hep.30941 Abstract 2294
The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries	Newsome	https://doi.org/10.1002/hep.30941 Abstract 395
Long-Term Outcomes of Patients with Advanced Fibrosis due to Non-Alcoholic Steatohepatitis (NASH) at Risk of Progressing to Cirrhosis Under Standard of Care	Pais	https://doi.org/10.1002/hep.30941 Abstract 1217

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
Long-Term Obeticholic Acid Treatment is Associated with Improvements in Collagen Morphometry in Patients with Primary Biliary Cholangitis	Kremer	https://doi.org/10.1016/S0168-8278(19)30204-1 Abstract 033
Long Term Assessment of the Effects of Obeticholic Acid in Patients with Primary Biliary Cholangitis on Immune and Inflammatory Markers	Hirschfield	https://doi.org/10.1016/S0168-8278(19)30204-1 Abstract 026
<i>NASH</i>		
Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH	Younossi	https://doi.org/10.1016/S0618-8278(19)30006-4 Abstract 06
Effect of Obeticholic Acid on Liver Function in Patients with Fibrosis due to NASH (Study 117: HepQuant Disease Severity Index in NASH)	Alkhoury	https://doi.org/10.1016/S0168-8278(19)30203-X Abstract 18

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

Intercept Presentations	First Author	Abstract Link
<i>Cholestasis</i>		
From Guidelines to Uniform Pan-healthcare Professional Practice: Development of an International Consensus Care Pathway for the Diagnosis and Management of Primary Biliary Cholangitis	Hirschfield	http://dx.doi.org/10.1002/hep.30257 Abstract 1886
Hepatic Safety Overview of Obeticholic Acid for the Treatment of Patients with Primary Biliary Cholangitis	Pockros	http://dx.doi.org/10.1002/hep.30257 Abstract 1931
<i>NASH</i>		
Obeticholic Acid Was Safe and Well Tolerated in Patients with NASH and Compensated Cirrhosis: A Secondary Analysis of the CONTROL Study	Halegoua-De Marzio	http://dx.doi.org/10.1002/hep.30256 Abstract 71
CONTROL: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Patients with Nonalcoholic Steatohepatitis	Pockros	https://doi.org/10.1002/hep.30257 Abstract 1672
Efficacy and Safety of Obeticholic Acid in Patient with Nonalcoholic Steatohepatitis and Significant Fibrosis Using Endpoint Definitions and Populations Accepted for Registrational Studies	Neuschwander-Tetri	http://dx.doi.org/10.1002/hep.30257 Abstract 1673
Safety, Pharmacokinetics and Pharmacodynamics of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	Alkhoury	http://dx.doi.org/10.1002/hep.30257 Abstract 1709

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested

EASL 2018 Intercept Presentations

Title	First Author	Abstract Link
Research		
Steroidal and non-steroidal FXR agonists elicit clinically-relevant lipoprotein profiles in mice with chimeric humanized livers	R. Papazyan	https://doi.org/10.1016/S0168-8278(18)30340-4
Cholestasis		
Long-Term Obeticholic Acid (OCA) Treatment Associated with Reversal or Stabilization of Fibrosis/Cirrhosis in Patients with Primary Biliary Cholangitis (PBC)	C.L. Bowlus	https://doi.org/10.1016/S0168-8278(18)30441-0
Change in Bilirubin with Obeticholic Acid Treatment in Primary Biliary Cholangitis Patients with High Baseline Bilirubin: A Retrospective Analysis of POISE, 201, and 202	G.M. Hirschfield	https://doi.org/10.1016/S0168-8278(18)30680-9
Durable Response in the Markers of Cholestasis through 36 Months of Open-Label Extension Study of Obeticholic Acid in Primary Biliary Cholangitis	M. Trauner	https://doi.org/10.1016/S0168-8278(18)30665-2
Independent Predictors of Primary Biliary Cholangitis (PBC) At High Risk for Progressive Course in the United States: Data from a Large-Real World Database	Z. Younossi	https://doi.org/10.1016/S0168-8278(18)30686-X
Primary Biliary Cholangitis in the U.S.: Real World Effectiveness of Obeticholic Acid in TARGET-PBC	C. Bowlus	https://doi.org/10.1016/S0168-8278(18)30673-1
Obeticholic acid response in primary biliary cholangitis associated with differential expression of antigen presentation, Wnt signalling and mRNA splicing	M. Seifi	https://doi.org/10.1016/S0168-8278(18)31133-4
Biliary Atresia		
Disease severity, obeticholic acid disposition and dose selection in patients with biliary atresia	J.E. Edwards	https://doi.org/10.1016/S0168-8278(18)31518-6
NASH		
Combined Administration of Obeticholic Acid (OCA) and GFT-505: Additive Histological Improvements in Mice with Diet-induced and Biopsy-confirmed Non-alcoholic Steatohepatitis (NASH)	J. Roth	https://doi.org/10.1016/S0168-8278(18)30913-9
Fibrosis involves increased fibroblast and hepatocyte collagen species, reflecting the interstitial and basement membrane matrix: Restoration of the local tissue milieu with FXR agonism	J. Roth	https://doi.org/10.1016/S0168-8278(18)31034-1
Treatment with obeticholic acid does not show liver enzyme elevations consistent with liver toxicity based upon evaluation of Drug-Induced Severe Hepatotoxicity (eDISH)	A. Sanyal	https://doi.org/10.1016/S0168-8278(18)31420-X

To request a presentation, please fill out a [medical information request form](#) with details of presentation being requested